Managers / Q1 2023 · view latest →
SR ONE CAPITAL MANAGEMENT, LP
CIK 0001910264 · 929 MAIN STREET, SUITE 200, REDWOOD CITY, CA, 94063 · (410) 800-7503
Summary
Sr One Capital Management, LP reported $268M in U.S.-listed holdings across 6 positions for Q1 2023.
The portfolio is heavily concentrated: ACLXGBX alone accounts for 63.1% of reported value.
Compared with Q4 2022, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 99.1% · $266M
- Other · 0.9% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MLYSMINERALYS THERAPEUTICS | NEW | +1.79M | 1.79M | +$28M | $28M |
| SPRYARS PHARMACEUTICALS | ADDED | +1.00M | 4.01M | +$451,455 | $26M |
| DSGNDESIGN THERAPEUTICS INC | HELD | +0 | 6.53M | −$29M | $38M |
| NKTXNKARTA INC. | HELD | +0 | 1.33M | −$3M | $5M |
| ACLXGBXARCELLX INC. | HELD | +0 | 5.50M | −$935,001 | $169M |
| EFFECTOR THERAPEUTICS INC | HELD | +0 | 6.82M | −$545,769 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACLXGBXARCELLX INC.history → | COMMON STOCK | 63.12% | $169M | 5.50M |
| 2 | DSGNDESIGN THERAPEUTICS INChistory → | COM | 14.03% | $38M | 6.53M |
| 3 | MLYSMINERALYS THERAPEUTICShistory → | COM | 10.47% | $28M | 1.79M |
| 4 | SPRYARS PHARMACEUTICALShistory → | COM | 9.73% | $26M | 4.01M |
| 5 | NKTXNKARTA INC.history → | COM | 1.76% | $5M | 1.33M |
| 6 | EFFECTOR THERAPEUTICS INC | COM | 0.89% | $2M | 6.82M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $915M | 14 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $706M | 13 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $691M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $461M | 13 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $389M | 12 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $410M | 11 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $499M | 11 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $319M | 9 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $364M | 6 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $238M | 5 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $195M | 6 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $232M | 6 | Aug 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $268M | 6 | May 19, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2022 | $274M | 5 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $219M | 4 | Nov 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $204M | 4 | Aug 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $195M | 3 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $177M | 2 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.